Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.

Trial Profile

A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals
  • Most Recent Events

    • 17 May 2018 According to a Sellas Life Sciences Group media release, the company will be conducting clinical and regulatory advisory board meetings at ASCO on May 30 and May 31 2018, based on the independent Data Safety Monitoring Board recommendation to seek regulatory guidance by the FDA.
    • 30 May 2014 New trial record
    • 06 Jun 2011 According to a RXi Pharmaceuticals media release, data presented at the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top